Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Shaheed Beheshti Medical University |
---|---|
Information provided by: | Shaheed Beheshti Medical University |
ClinicalTrials.gov Identifier: | NCT00899587 |
In this study, patients were divided into 3 group with 35 cases including: 1.oxygen 2.enalapril 3.control.
In the beginning of the study, best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), and optical coherence tomography (OCT) were measured. Patients in the oxygen group were given oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month. In the enalapril group, patients were given enalapril 5 mg every night and placebo was given for the patients in third group. At the end of first month the patients' vision was checked again and at the the end of the third month the first physical examinations were performed. In the first group, arterial blood gas (ABG) was taken before and after oxygen therapy as well.
Condition | Intervention | Phase |
---|---|---|
Diabetic Macular Ischemia |
Drug: enalapril Other: oxygen Drug: placebo |
Phase I |
Study Type: | Interventional |
Official Title: | Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia |
Arms | Assigned Interventions |
---|---|
Oxygen: Experimental |
Other: oxygen
oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
|
Enalapril: Experimental |
Drug: enalapril
enalapril 5 mg every night
|
Control: Placebo Comparator | Drug: placebo |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contact: Masoud Soheilian, MD | +982122585952 | labbafi@hotmail.com |
Iran, Islamic Republic of | |
Ophthalmic Research Center | Recruiting |
Tehran, Iran, Islamic Republic of, 166666 | |
Contact: Masoud Soheilian, MD +98 21 22585952 labbafi@hotmail.com |
Study ID Numbers: | 8753 |
Study First Received: | May 11, 2009 |
Last Updated: | May 11, 2009 |
ClinicalTrials.gov Identifier: | NCT00899587 History of Changes |
Health Authority: | Iran: Ethics Committee |
Enalapril Enalaprilat Angiotensin-Converting Enzyme Inhibitors Cardiovascular Agents |
Ischemia Antihypertensive Agents Protease Inhibitors |
Enalapril Pathologic Processes Molecular Mechanisms of Pharmacological Action Enalaprilat Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors |
Enzyme Inhibitors Cardiovascular Agents Ischemia Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |